GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-20: Form 6-K; Period of report 2016-12-20; Description VIIV STARTS HIV PREVENTION STUDY WITH CABOTEGRAVIR; Document a3856s.htm.
- 2016-12-20: Form 6-K; Period of report 2016-12-20; Description BLOCKLISTING APPLICATION; Document a3269s.htm.
- 2016-12-20: Form 6-K; Period of report 2016-12-20; Description VIIV ANNOUNCE PHASE III RESULTS FOR 2-DRUG REGIMEN; Document a2970s.htm.
- 2016-12-19: Form 6-K; Period of report 2016-12-19; Description DIRECTORATE CHANGE; Document a2751s.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2016-12-20 | 6-K | 2016-12-20 | VIIV STARTS HIV PREVENTION STUDY WITH CABOTEGRAVIR | a3856s.htm |
| 2016-12-20 | 6-K | 2016-12-20 | BLOCKLISTING APPLICATION | a3269s.htm |
| 2016-12-20 | 6-K | 2016-12-20 | VIIV ANNOUNCE PHASE III RESULTS FOR 2-DRUG REGIMEN | a2970s.htm |
| 2016-12-19 | 6-K | 2016-12-19 | DIRECTORATE CHANGE | a2751s.htm |
| 2016-12-19 | 6-K | 2016-12-19 | PHASE III STUDY START FOR CLOSED TRIPLE IN ASTHMA | a2284s.htm |
| 2016-12-16 | 6-K | 2016-12-16 | TREASURY STOCK | a1621s.htm |
| 2016-12-16 | 6-K | 2016-12-16 | DIRECTOR/PDMR SHAREHOLDING | a0827s.htm |
| 2016-12-13 | 6-K | 2016-12-13 | AUDIT TENDER CONCLUSION | a7092r.htm |
| 2016-12-12 | 6-K | 2016-12-12 | DIRECTOR/PDMR SHAREHOLDING | a6123r.htm |
| 2016-12-02 | 6-K | 2016-12-02 | DIRECTOR/PDMR SHAREHOLDING | a8688q.htm |
| 2016-12-02 | 6-K | 2016-12-02 | GSK FILES CLOSED TRIPLE THERAPY FOR COPD IN EU | a8571q.htm |
| 2016-12-02 | 6-K | 2016-12-02 | RELVAR ELLIPTA APPROVED IN JAPAN FOR COPD | a7954q.htm |
| 2016-12-01 | 6-K | 2016-12-01 | TOTAL VOTING RIGHTS | a7069q.htm |
| 2016-11-30 | 6-K | 2016-11-30 | DIRECTOR/PDMR SHAREHOLDING | a6111q.htm |
| 2016-11-25 | 6-K | 2016-11-25 | EU SUBMISSION OF SHINGLES CANDIDATE VACCINE | a2101q.htm |
| 2016-11-25 | 6-K | 2016-11-24 | START OF PHASE III STUDIES WITH DAPRODUSTAT | a0824q.htm |
| 2016-11-23 | 6-K | 2016-11-23 | MEPOLIZUMAB MEETS ENDPOINTS IN PHASE 3 EGPA STUDY | a9172p.htm |
| 2016-11-21 | 6-K | 2016-11-21 | GSK FILES CLOSED TRIPLE THERAPY FOR COPD IN US | a6614p.htm |
| 2016-11-18 | 6-K | 2016-11-18 | VIIV STARTS PHIII LA INJECTABLE TREATMENT REGIMEN | a6086p.htm |
| 2016-11-16 | 6-K | 2016-11-16 | NEW PHASE III DATA OF SIRUKUMAB FOR RA | a3782p.htm |
| 2016-11-10 | 6-K | 2016-11-10 | DIRECTOR/PDMR SHAREHOLDING | a9075o.htm |
| 2016-11-08 | 6-K | 2016-11-08 | DIRECTOR/PDMR SHAREHOLDING | a6698o.htm |
| 2016-11-08 | 6-K | 2016-11-08 | BLOCK LISTING INTERIM REVIEW | a6705o.htm |
| 2016-11-04 | 6-K | 2016-11-04 | DIRECTOR/PDMR SHAREHOLDING | a4307o.htm |
| 2016-11-02 | 6-K | 2016-11-02 | DIRECTOR/PDMR SHAREHOLDING | a1828o.htm |
| 2016-11-01 | 6-K | 2016-11-01 | TOTAL VOTING RIGHTS | a9897n.htm |
| 2016-10-28 | 6-K | 2016-10-28 | DIRECTOR/PDMR SHAREHOLDING | a7739n.htm |
| 2016-10-27 | 6-K | 2016-10-27 | DIRECTOR/PDMR SHAREHOLDING | a6736n.htm |
| 2016-10-27 | 6-K | 2016-10-27 | GSK ISSUES NEW DATA ON SHINGLES CANDIDATE VACCINE | a6424n.htm |
| 2016-10-26 | 6-K | 2016-10-26 | 3RD QUARTER RESULTS | q3201626oct_sefinal2000.htm |
| 2016-10-26 | 6-K | 2016-10-26 | DIRECTOR/PDMR SHAREHOLDING | a5582n.htm |
| 2016-10-26 | 6-K | 2016-10-26 | DIRECTOR/PDMR SHAREHOLDING | a5493n.htm |
| 2016-10-25 | 6-K | 2016-10-25 | DIRECTOR/PDMR SHAREHOLDING | a4214n.htm |
| 2016-10-24 | 6-K | 2016-10-24 | US FDA SUBMISSION OF SHINGLES CANDIDATE VACCINE | a2616n.htm |
| 2016-10-21 | 6-K | 2016-10-21 | DIRECTOR/PDMR SHAREHOLDING | a2194n.htm |
| 2016-10-18 | 6-K | 2016-10-18 | DIRECTOR/PDMR SHAREHOLDING | a7622m.htm |
| 2016-10-18 | 6-K | 2016-10-18 | DIRECTOR/PDMR SHAREHOLDING | a7609m.htm |
| 2016-10-18 | 6-K | 2016-10-17 | DIRECTOR/PDMR SHAREHOLDING | a7603m.htm |
| 2016-10-18 | 6-K | 2016-10-17 | DIRECTOR/PDMR SHAREHOLDING | a7597m.htm |
| 2016-10-17 | 6-K | 2016-10-17 | DIRECTOR/PDMR SHAREHOLDING | a7585m.htm |
| 2016-10-17 | 6-K | 2016-10-17 | DIRECTOR/PDMR SHAREHOLDING | a7592m.htm |
| 2016-10-17 | 6-K | 2016-10-17 | DIRECTOR/PDMR SHAREHOLDING | a7588m.htm |
| 2016-10-14 | 6-K | 2016-10-14 | DIRECTOR/PDMR SHAREHOLDING | a6268m.htm |
| 2016-10-14 | 6-K | 2016-10-14 | DIRECTOR/PDMR SHAREHOLDING | a6289m.htm |
| 2016-10-14 | 6-K | 2016-10-14 | PRIMARY DOCUMENT | a6263m.htm |
| 2016-10-12 | 6-K | 2016-10-12 | DIRECTOR/PDMR SHAREHOLDING | a4000m.htm |
| 2016-10-11 | 6-K | 2016-10-11 | DIRECTOR/PDMR SHAREHOLDING | a1600m.htm |
| 2016-10-03 | 6-K | 2016-10-03 | TOTAL VOTING RIGHTS | a4903l.htm |
| 2016-09-29 | 6-K | 2016-09-29 | DIRECTOR/PDMR SHAREHOLDING | a2018l.htm |
| 2016-09-26 | 6-K | 2016-09-26 | DIRECTOR/PDMR SHAREHOLDING | a8631k.htm |
| 2016-09-26 | 6-K | 2016-09-26 | DIRECTOR/PDMR SHAREHOLDING | a8621k.htm |
| 2016-09-23 | 6-K | 2016-09-23 | US REGULATORY SUBMISSION FOR SIRUKUMAB IN RA | a7004k.htm |
| 2016-09-20 | 6-K | 2016-09-20 | GSK APPOINTS NEW CEO | a2876k.htm |
| 2016-09-19 | 6-K | 2016-09-19 | DIRECTOR/PDMR SHAREHOLDING | a2359k.htm |
| 2016-09-15 | 6-K | 2016-09-15 | RESULTS PHASE III STUDY SHINGRIX VACCINE IN NEJM | a8837j.htm |
| 2016-09-12 | 6-K | 2016-09-12 | DIRECTOR/PDMR SHAREHOLDING | a6109j.htm |
| 2016-09-12 | 6-K | 2016-09-12 | EU REGULATORY SUBMISSION FOR SIRUKUMAB IN RA | a5847j.htm |
| 2016-09-06 | 6-K | 2016-09-06 | RESULTS OF PHASE III FULFIL STUDY PRESENTED AT ERS | a1100j.htm |
| 2016-09-06 | 6-K | 2016-09-06 | POSITIVE RESULTS FROM THE COPD SALFORD LUNG STUDY | a8931i.htm |
| 2016-09-01 | 6-K | 2016-09-01 | TOTAL VOTING RIGHTS | a7310i.htm |
| 2016-08-30 | 6-K | 2016-08-30 | DIRECTOR/PDMR SHAREHOLDING | a4392i.htm |
| 2016-08-23 | 6-K | 2016-08-23 | DIRECTOR/PDMR SHAREHOLDING | a9405h.htm |
| 2016-08-16 | 6-K | 2016-08-16 | DIRECTOR/PDMR SHAREHOLDING | a3434h000.htm |
| 2016-08-16 | 6-K | 2016-08-16 | VIIV STARTS PHIII PROGRAMME FOR DOLUTEGRAVIR & 3TC | a3247h.htm |
| 2016-08-12 | 6-K | 2016-08-12 | DIRECTOR/PDMR SHAREHOLDING | a1069h.htm |
| 2016-08-10 | 6-K | 2016-08-10 | DIRECTOR/PDMR SHAREHOLDING | a8465g.htm |
| 2016-08-09 | 6-K | 2016-08-09 | DIRECTOR/PDMR SHAREHOLDING | a7283g.htm |
| 2016-08-04 | 6-K | 2016-08-04 | PUBLICATION OF A PROSPECTUS | a3131g.htm |
| 2016-08-01 | 6-K | 2016-08-01 | TOTAL VOTING RIGHTS | a8446f.htm |
| 2016-08-01 | 6-K | 2016-08-01 | DIRECTOR/PDMR SHAREHOLDING | a8809f.htm |
| 2016-08-01 | 6-K | 2016-08-01 | GSK AND VERILY TO ESTABLISH GALVANI BIOELECTRONICS | a7908f.htm |
| 2016-07-28 | 6-K | 2016-07-28 | DIRECTOR/PDMR SHAREHOLDING | a5892f.htm |
| 2016-07-27 | 6-K | 2016-07-27 | HALF-YEAR REPORT | a160727solxq2201627july_f000.htm |
| 2016-07-25 | 6-K | 2016-07-25 | DIRECTOR/PDMR SHAREHOLDING | a1642f.htm |
| 2016-07-20 | 6-K | 2016-07-20 | PRIMARY DOCUMENT | a7906e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6694e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6693e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6689e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6687e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6686e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6684e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6683e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6682e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6676e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6675e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6672e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6696e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6670e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6669e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6668e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6666e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6656e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6651e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6648e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6644e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6643e.htm |
| 2016-07-20 | 6-K | 2016-07-20 | DIRECTOR/PDMR SHAREHOLDING | a6640e.htm |
| 2016-07-19 | 6-K | 2016-07-19 | DIRECTOR/PDMR SHAREHOLDING | a6628e.htm |
| 2016-07-19 | 6-K | 2016-07-19 | DIRECTOR/PDMR SHAREHOLDING | a6624e.htm |
| 2016-07-19 | 6-K | 2016-07-19 | DIRECTOR/PDMR SHAREHOLDING | a6619e.htm |